Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model

Muhammad M. Mohiuddin, Avneesh Singh, Philip C. Corcoran, Robert F. Hoyt, Marvin L. Thomas, Billeta G T Lewis, Michael Eckhaus, Nicole L. Dabkowski, Aaron J. Belli, Keith A. Reimann, David Ayares, Keith A. Horvath

Research output: Contribution to journalArticle

Abstract

Background Recently, we have shown that an immunosuppression regimen including costimulation blockade via anti-CD154 antibody significantly prolongs the cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon heterotopic xenotransplantation model. Unfortunately, many coagulation disorders were observed with the use of anti-CD154 antibody, and recipient survival was markedly reduced by these complications. Material and Methods In this experiment, we replaced anti-CD154 antibody with a more clinically acceptable anti-CD40 antibody while keeping the rest of the immunosuppressive regimen and the donor pig genetics the same. This was carried out to evaluate the antibody's role in xenograft survival and prevention of coagulopathies. Two available clones of anti-CD40 antibody were tested. One mouse anti-human CD40 antibody, (clone 3A8), activated B lymphocytes in vitro and only modestly suppressed antibody production in vivo. Whereas a recombinant mouse non-human primate chimeric raised against macaque CD40, (clone 2C10R4), blocked B-cell activation in vitro and completely blocked antibody production in vivo. Results The thrombotic complications seen with anti-CD154 antibody were effectively avoided but the graft survival, although extended, was not as prolonged as observed with anti-CD154 antibody treatment. The longest survival for the 3A8 antibody group was 27 days, and the longest graft survival in the 2C10R4 antibody group was 146 days. All of the grafts except two rejected and were explanted. Only two recipient baboons had to be euthanized due to unrelated complications, and the rest of the baboons remained healthy throughout the graft survival period or after graft explantation. In contrast to our anti-CD 154 antibody-treated baboons, the non-Gal antibody levels started to rise after B cells made their appearance around 8 weeks post-transplantation. Conclusions Anti-CD40 antibody at the current dose does not induce any coagulopathies but while effective, had reduced efficacy to induce similar long-term graft survival as with anti-CD154 antibody perhaps due to ineffective control of B-cell function and antibody production at the present dose. More experiments are required to determine antibody affinity and effective dose for inducing long-term cardiac xenograft survival.

Original languageEnglish (US)
Pages (from-to)35-45
Number of pages11
JournalXenotransplantation
Volume21
Issue number1
DOIs
StatePublished - Jan 2014
Externally publishedYes

Fingerprint

Papio
Heterografts
Antibody Formation
Anti-Idiotypic Antibodies
Swine
Graft Survival
Antibodies
B-Lymphocytes
Clone Cells
Transplants
Heterologous Transplantation
Antibody Affinity
Survival
Macaca
Immunosuppressive Agents
Immunosuppression
Primates
Transplantation

Keywords

  • 2C10R4
  • Anti-CD40 antibody
  • cardiac xenograft
  • CD46
  • Gal KO pigs
  • non-Gal antibodies
  • xenotransplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology
  • Medicine(all)

Cite this

Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model. / Mohiuddin, Muhammad M.; Singh, Avneesh; Corcoran, Philip C.; Hoyt, Robert F.; Thomas, Marvin L.; Lewis, Billeta G T; Eckhaus, Michael; Dabkowski, Nicole L.; Belli, Aaron J.; Reimann, Keith A.; Ayares, David; Horvath, Keith A.

In: Xenotransplantation, Vol. 21, No. 1, 01.2014, p. 35-45.

Research output: Contribution to journalArticle

Mohiuddin, MM, Singh, A, Corcoran, PC, Hoyt, RF, Thomas, ML, Lewis, BGT, Eckhaus, M, Dabkowski, NL, Belli, AJ, Reimann, KA, Ayares, D & Horvath, KA 2014, 'Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model', Xenotransplantation, vol. 21, no. 1, pp. 35-45. https://doi.org/10.1111/xen.12066
Mohiuddin, Muhammad M. ; Singh, Avneesh ; Corcoran, Philip C. ; Hoyt, Robert F. ; Thomas, Marvin L. ; Lewis, Billeta G T ; Eckhaus, Michael ; Dabkowski, Nicole L. ; Belli, Aaron J. ; Reimann, Keith A. ; Ayares, David ; Horvath, Keith A. / Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model. In: Xenotransplantation. 2014 ; Vol. 21, No. 1. pp. 35-45.
@article{d52bd36df1524aa48e9dfbe7913b7b8d,
title = "Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model",
abstract = "Background Recently, we have shown that an immunosuppression regimen including costimulation blockade via anti-CD154 antibody significantly prolongs the cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon heterotopic xenotransplantation model. Unfortunately, many coagulation disorders were observed with the use of anti-CD154 antibody, and recipient survival was markedly reduced by these complications. Material and Methods In this experiment, we replaced anti-CD154 antibody with a more clinically acceptable anti-CD40 antibody while keeping the rest of the immunosuppressive regimen and the donor pig genetics the same. This was carried out to evaluate the antibody's role in xenograft survival and prevention of coagulopathies. Two available clones of anti-CD40 antibody were tested. One mouse anti-human CD40 antibody, (clone 3A8), activated B lymphocytes in vitro and only modestly suppressed antibody production in vivo. Whereas a recombinant mouse non-human primate chimeric raised against macaque CD40, (clone 2C10R4), blocked B-cell activation in vitro and completely blocked antibody production in vivo. Results The thrombotic complications seen with anti-CD154 antibody were effectively avoided but the graft survival, although extended, was not as prolonged as observed with anti-CD154 antibody treatment. The longest survival for the 3A8 antibody group was 27 days, and the longest graft survival in the 2C10R4 antibody group was 146 days. All of the grafts except two rejected and were explanted. Only two recipient baboons had to be euthanized due to unrelated complications, and the rest of the baboons remained healthy throughout the graft survival period or after graft explantation. In contrast to our anti-CD 154 antibody-treated baboons, the non-Gal antibody levels started to rise after B cells made their appearance around 8 weeks post-transplantation. Conclusions Anti-CD40 antibody at the current dose does not induce any coagulopathies but while effective, had reduced efficacy to induce similar long-term graft survival as with anti-CD154 antibody perhaps due to ineffective control of B-cell function and antibody production at the present dose. More experiments are required to determine antibody affinity and effective dose for inducing long-term cardiac xenograft survival.",
keywords = "2C10R4, Anti-CD40 antibody, cardiac xenograft, CD46, Gal KO pigs, non-Gal antibodies, xenotransplantation",
author = "Mohiuddin, {Muhammad M.} and Avneesh Singh and Corcoran, {Philip C.} and Hoyt, {Robert F.} and Thomas, {Marvin L.} and Lewis, {Billeta G T} and Michael Eckhaus and Dabkowski, {Nicole L.} and Belli, {Aaron J.} and Reimann, {Keith A.} and David Ayares and Horvath, {Keith A.}",
year = "2014",
month = "1",
doi = "10.1111/xen.12066",
language = "English (US)",
volume = "21",
pages = "35--45",
journal = "Xenotransplantation",
issn = "0908-665X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Role of anti-CD40 antibody-mediated costimulation blockade on non-Gal antibody production and heterotopic cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon model

AU - Mohiuddin, Muhammad M.

AU - Singh, Avneesh

AU - Corcoran, Philip C.

AU - Hoyt, Robert F.

AU - Thomas, Marvin L.

AU - Lewis, Billeta G T

AU - Eckhaus, Michael

AU - Dabkowski, Nicole L.

AU - Belli, Aaron J.

AU - Reimann, Keith A.

AU - Ayares, David

AU - Horvath, Keith A.

PY - 2014/1

Y1 - 2014/1

N2 - Background Recently, we have shown that an immunosuppression regimen including costimulation blockade via anti-CD154 antibody significantly prolongs the cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon heterotopic xenotransplantation model. Unfortunately, many coagulation disorders were observed with the use of anti-CD154 antibody, and recipient survival was markedly reduced by these complications. Material and Methods In this experiment, we replaced anti-CD154 antibody with a more clinically acceptable anti-CD40 antibody while keeping the rest of the immunosuppressive regimen and the donor pig genetics the same. This was carried out to evaluate the antibody's role in xenograft survival and prevention of coagulopathies. Two available clones of anti-CD40 antibody were tested. One mouse anti-human CD40 antibody, (clone 3A8), activated B lymphocytes in vitro and only modestly suppressed antibody production in vivo. Whereas a recombinant mouse non-human primate chimeric raised against macaque CD40, (clone 2C10R4), blocked B-cell activation in vitro and completely blocked antibody production in vivo. Results The thrombotic complications seen with anti-CD154 antibody were effectively avoided but the graft survival, although extended, was not as prolonged as observed with anti-CD154 antibody treatment. The longest survival for the 3A8 antibody group was 27 days, and the longest graft survival in the 2C10R4 antibody group was 146 days. All of the grafts except two rejected and were explanted. Only two recipient baboons had to be euthanized due to unrelated complications, and the rest of the baboons remained healthy throughout the graft survival period or after graft explantation. In contrast to our anti-CD 154 antibody-treated baboons, the non-Gal antibody levels started to rise after B cells made their appearance around 8 weeks post-transplantation. Conclusions Anti-CD40 antibody at the current dose does not induce any coagulopathies but while effective, had reduced efficacy to induce similar long-term graft survival as with anti-CD154 antibody perhaps due to ineffective control of B-cell function and antibody production at the present dose. More experiments are required to determine antibody affinity and effective dose for inducing long-term cardiac xenograft survival.

AB - Background Recently, we have shown that an immunosuppression regimen including costimulation blockade via anti-CD154 antibody significantly prolongs the cardiac xenograft survival in a GTKO.hCD46Tg pig-to-baboon heterotopic xenotransplantation model. Unfortunately, many coagulation disorders were observed with the use of anti-CD154 antibody, and recipient survival was markedly reduced by these complications. Material and Methods In this experiment, we replaced anti-CD154 antibody with a more clinically acceptable anti-CD40 antibody while keeping the rest of the immunosuppressive regimen and the donor pig genetics the same. This was carried out to evaluate the antibody's role in xenograft survival and prevention of coagulopathies. Two available clones of anti-CD40 antibody were tested. One mouse anti-human CD40 antibody, (clone 3A8), activated B lymphocytes in vitro and only modestly suppressed antibody production in vivo. Whereas a recombinant mouse non-human primate chimeric raised against macaque CD40, (clone 2C10R4), blocked B-cell activation in vitro and completely blocked antibody production in vivo. Results The thrombotic complications seen with anti-CD154 antibody were effectively avoided but the graft survival, although extended, was not as prolonged as observed with anti-CD154 antibody treatment. The longest survival for the 3A8 antibody group was 27 days, and the longest graft survival in the 2C10R4 antibody group was 146 days. All of the grafts except two rejected and were explanted. Only two recipient baboons had to be euthanized due to unrelated complications, and the rest of the baboons remained healthy throughout the graft survival period or after graft explantation. In contrast to our anti-CD 154 antibody-treated baboons, the non-Gal antibody levels started to rise after B cells made their appearance around 8 weeks post-transplantation. Conclusions Anti-CD40 antibody at the current dose does not induce any coagulopathies but while effective, had reduced efficacy to induce similar long-term graft survival as with anti-CD154 antibody perhaps due to ineffective control of B-cell function and antibody production at the present dose. More experiments are required to determine antibody affinity and effective dose for inducing long-term cardiac xenograft survival.

KW - 2C10R4

KW - Anti-CD40 antibody

KW - cardiac xenograft

KW - CD46

KW - Gal KO pigs

KW - non-Gal antibodies

KW - xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=84893855969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893855969&partnerID=8YFLogxK

U2 - 10.1111/xen.12066

DO - 10.1111/xen.12066

M3 - Article

VL - 21

SP - 35

EP - 45

JO - Xenotransplantation

JF - Xenotransplantation

SN - 0908-665X

IS - 1

ER -